Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Anti-GD2 and Expanded, Activated Natural Killer Cell Infusion for Neuroblastoma

NCT03242603 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT03242603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03242603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Anti-GD2 and Expanded, Activated Natural Killer Cell Infusion for Neuroblastoma
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 3, 2017
Completion date
August 15, 2020
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma recurrent